CClinicalTrials.gg
CompletedNCT05019378Updated Aug 26, 2021

SVF Therapy for Human Knee Osteoarthritis

An interventional study of SVF treatment in Knee Osteoarthritis, sponsored by Zhongnan Hospital. Completed at 1 site in China. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-26.

Sponsored by Zhongnan Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 7 months after the study started (first participant enrolled Dec 2016, registered Aug 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

The purpose of the study is to asses the safety and efficacy of SVF for treatment of knee osteoarthritis, and establish a novel method to provide 3D MRI imaging for human knee cartilage to qualitatively and quantitatively evaluate cartilage regeneration.

Read the detailed description

Study participants voluntarily provided written informed consent to participate in the study. The two knees of each patient were randomly assigned to autologous SVF treatment group or non-treatment control group. The patients were evaluated every 4 weeks for safety and efficacy of autologous SVF therapy for 24 weeks.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Cartilage Defect
  • Cartilage Regeneration
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 6 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Zhongnan Hospital is the lead sponsor of 103 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Clinical diagnosis of Knee Osteoarthritis
  • Articular cartilage defect grades I/II of both knee

Exclusion criteria

Exclusion Criteria:

  • autoimmune or inflammatory arthritis
  • serious medical disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    autologous SVF treatment

    Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint

    Procedure: SVF treatment

  • No intervention
    Placebo group

    No treatment

Interventions

  • ProcedureSVF treatment

    autologous SVF (10E8 cells)

06

What researchers measure

Primary outcomes

  1. Radiologic evaluation of knee articular cartilage Volume

    The Volume (cubic millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Volume at 12 weeks

  2. Radiologic evaluation of knee articular cartilage Volume

    The Volume (cubic millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Volume at 24 weeks

  3. Radiologic evaluation of knee articular cartilage Area

    The Area (square millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Area at 12 weeks

  4. Radiologic evaluation of knee articular cartilage Area

    The Area (square millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Area at 24 weeks

  5. Radiologic evaluation of knee articular cartilage Thickness

    The Thickness (millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Thickness at 12 weeks

  6. Radiologic evaluation of knee articular cartilage Thickness

    The Thickness (millimeter) of knee articular cartilage are measured.

    Time frame: Change from Baseline articular cartilage Thickness at 24 weeks

  7. Knee pain evaluation and functional evaluation (the Western Ontario and McMaster University arthritis index [WOMAC])

    Knee pain and functional mobility were assessed using WOMAC arthritis index patient questionnaire including 24 parameters for pain, stiffness and physical function. The values ranging from 0 (minimum) to 240 (maximum) and the lower scores mean a better outcome.

    Time frame: Change from Baseline WOMAC arthritis index score at 12 weeks.

  8. Knee pain evaluation and functional evaluation (the Western Ontario and McMaster University arthritis index [WOMAC])

    Knee pain and functional mobility were assessed using WOMAC arthritis index patient questionnaire including 24 parameters for pain, stiffness and physical function. The values ranging from 0 (minimum) to 240 (maximum) and the lower scores mean a better outcome.

    Time frame: Change from Baseline WOMAC arthritis index score at 24 weeks.

  9. Knee pain evaluation and functional evaluation (The Lysholm Knee Scoring Scale)

    The Lysholm Knee Scoring Scale questionnaire has been designed to evaluate how patients' knee pain has affected their ability to manage everyday life. The values ranging from 0 (minimum) to 100 (maximum) and the higher scores mean a better outcome.

    Time frame: Change from Baseline Lysholm Knee Scale score at 12 weeks.

  10. Knee pain evaluation and functional evaluation (The Lysholm Knee Scale)

    The Lysholm Knee Scoring Scale questionnaire has been designed to evaluate how patients' knee pain has affected their ability to manage everyday life. The values ranging from 0 (minimum) to 100 (maximum) and the higher scores mean a better outcome.

    Time frame: Change from Baseline Lysholm Knee Scale score at 24 weeks.

07

Study locations

1 site
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 437200, China
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD, all IPD that underlie results in a publication

Supporting information: Study protocol, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05019378
Lead sponsor
Zhongnan Hospital
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Dec 19, 2016
Primary completion
Aug 23, 2018
Completion
Jan 28, 2019
Last update
Aug 26, 2021

Study contacts

Xin Xiao Zheng, MD
principal investigator · Wuhan University
Lin Cai, MD
study director · Wuhan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion